Pharmaceutical Technology on MSN3d
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitorMSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties ...
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...
US pharma giant Merck & Co and China’s Jiangsu Hengrui Pharmaceuticals have entered into an exclusive license agreement for ...
Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...
Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...
Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback